Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Athira Pharma Inc (NQ: ATHA )

2.450 +0.050 (+2.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 194,500
Open 2.360
Bid (Size) 2.440 (2)
Ask (Size) 2.450 (8)
Prev. Close 2.400
Today's Range 2.355 - 2.465
52wk Range 2.335 - 14.22
Shares Outstanding 37,944,190
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences
Company to highlight potential of its small molecule therapeutics that enhance the HGF/MET system to treat a variety of neurodegenerative diseases 
From Athira Pharma, Inc.
Via Globe NewsWire

Performance

YTD
-27.51%
-27.51%
1 Month
-24.62%
-24.62%
3 Month
-17.79%
-17.79%
6 Month
-18.60%
-18.60%
1 Year
-80.77%
-80.77%

More News

Read More
Athira Pharma, Inc. (NASDAQ:ATHA) Investor Alert: Investigation over Potential Wrongdoing
Via SBWire
Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Outlines Possible Comeback For Alzheimer's Candidate
Via Benzinga
Johnson & Johnson: Taking The Bull By The Horns?
Via MarketBeat
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Regulatory
Athira Pharma Announces Publication in Journal of Alzheimer’s Disease Highlighting Need for Novel Alzheimer’s Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Pharma: Q2 Earnings Insights
Via Benzinga
NASDAQ:ATHA Shareholder Notice: Update in Lawsuit Against Athira Pharma, Inc.
Via SBWire
Athira Pharma Provides 2023 Pipeline Outlook
From Athira Pharma, Inc.
Via Globe NewsWire
4 Penny Stocks Insiders Are Buying: Athira Pharma, Great Elm Group And More
Via Benzinga
Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics
From Athira Pharma, Inc.
Via Globe NewsWire
Beachbody, Athira Pharma And This Penny Stock Insiders Are Aggressively Buying
Via Benzinga
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 –3:30 pm Eastern time
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD Conference
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From Athira Pharma, Inc.
Via Globe NewsWire
Around $4 Million Bet On Lesaka Technologies? Check Out These 4 Penny Stocks Insiders Are Buying
Via Benzinga
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Pharma to Present at Stifel 2022 Healthcare Conference
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis
From Athira Pharma, Inc.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.